false
English
Catalog
2025 Targeted Therapies of Lung Cancer (TTLC) - Po ...
PP01.31 Decoding First-line strategies in EGFR-mut ...
PP01.31 Decoding First-line strategies in EGFR-mutated NSCLC: A Computational Analysis of FLAURA2 vs. MARIPOSA
Back to course
Pdf Summary
This study aims to evaluate the efficacy of two first-line treatment strategies, FLAURA2 and MARIPOSA, for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The analysis focuses on comparing the combination therapies of osimertinib with chemotherapy versus amivantamab with lazertinib. Using a computational method, Individual Patient Data (IPD) was reconstructed from Kaplan-Meier survival plots to assess progression-free survival (PFS) and overall survival (OS) for patients. <br /><br />The results indicate that patients receiving osimertinib-chemotherapy had a superior median PFS of 26.1 months compared to 22.6 months in the amivantamab-lazertinib group. The hazard ratio was 0.79, suggesting osimertinib-chemotherapy is more effective (p=0.043). OS data is still not fully mature, as analyses at the 12- and 24-month benchmarks showed no statistically significant differences between the two therapies.<br /><br />Importantly, osimertinib-chemotherapy showed notable efficacy in high-risk subgroups. Patients with central nervous system (CNS) metastases had significantly improved 12-month and 24-month survival rates compared to amivantamab-lazertinib. Additionally, patients with TP53 co-mutations demonstrated better survival rates with osimertinib-chemotherapy at both 12- and 24-month milestones.<br /><br />The study concludes that osimertinib-chemotherapy provides superior efficacy, especially for high-risk patients with EGFR-mutated NSCLC, compared to the amivantamab-lazertinib regimen. Nevertheless, the authors recommend further head-to-head prospective studies to confirm the most effective frontline treatment strategy for this patient group.
Asset Subtitle
Sanad Alhushki
Keywords
EGFR-mutated NSCLC
FLAURA2
MARIPOSA
osimertinib
chemotherapy
amivantamab
lazertinib
progression-free survival
central nervous system metastases
TP53 co-mutations
×
Please select your language
1
English
5
普通话
11
Dutch